Young people living with HIV manage their condition better when their antiretroviral therapy is given by injections every eight weeks rather than as daily tablets, according to research from University College London (UCL). The findings were published in The Lancet.
The study focused on young people, a group that often struggles with daily adherence to medication. Poor adherence can lead to treatment failure and the development of drug-resistant HIV. Long-acting injectable regimens offer an alternative that removes the need for a daily pill.
According to the UCL news release, participants receiving the injectable therapy achieved better viral suppression compared with those on daily oral tablets. The research adds to a growing body of evidence supporting long-acting injectable antiretroviral therapy as a viable option for people living with HIV.
Further details, including the exact number of participants and the duration of follow-up, were not available in the source material. The full paper in The Lancet should be consulted for complete methodology and results.
